Expanded access programmes: Patient interests versus clinical trial integrity

The Lancet Oncology

Volumn 16, Issue 1, 2015, Pages 15-17

  Lorigan, Paul ^a   Ascierto, Paolo A ^b   Dummer, Reinhard ^c   Eggermont, Alexander M ^d   Flaherty, Keith T ^e   Garbe, Claus ^f   Gogas, Helen ^g   Hauschild, Axel ^h   Kefford, Richard F ^i,j,k   Kirkwood, John M ^m   Larkin, James ⁿ   Long, Georgina V ^i,j   Maio, Michele ^l   McArthur, Grant A ^o   Ribas, Antoni ^p   Robert, Caroline ^n,q   Schadendorf, Dirk ^r   Sondak, Vernon K ^s   Wolchok, Jedd D ^t   Hudson, Andrew M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ MELANOMA INSTITUTE AUSTRALIA   (Australia)

^j UNIVERSITY OF SYDNEY   (Australia)

^k MACQUARIE UNIVERSITY   (Australia)

^l UNIVERSITY HOSPITAL OF SIENA   (Italy)

^m UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

ⁿ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^o UNIVERSITY OF MELBOURNE   (Australia)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q Universite Paris Sud   (France)

^r UNIVERSITY HOSPITAL ESSEN   (Germany)

^s H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^t MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TICILIMUMAB;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COMPASSIONATE USE; DRUG APPROVAL; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; DRUG SEEKING BEHAVIOR; HEALTH CARE ACCESS; HUMAN; LONG TERM SURVIVAL; NOTE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; ETHICS; HEALTH CARE DELIVERY; PATIENT RIGHT; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTOR;

CLINICAL TRIALS AS TOPIC; COMPASSIONATE USE TRIALS; HEALTH SERVICES ACCESSIBILITY; HUMANS; PATIENT RIGHTS; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84927635228     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71161-1     Document Type: Note

References (10)

1. Final rules for expanded access to investigational drugs for treatment use and charging for investigational drugs US Food and Drug Administration, (accessed June 5, 2014). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm351748.htm.
2. Early access to medicines scheme Medicines and Healthcare products Regulatory Agency, (accessed June 5, 2014). http://www.mhra.gov.uk/Howweregulate/Medicines/MISGNewTechnologiesAdvisoryPanel/Earlieraccesstonewmedicinesintheuk/index.htm.
3. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
4. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
5. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014, 32:1020-1030.
6. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013, 31:616-622.
7. Ribas A, Hauschild A, Kefford R Reply to KS Wilson et al. J Clin Oncol 2013, 31:2836-2837.
8. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013, 310:2191-2194.
9. Flaherty KT, Hennig M, Lee SJ, et al. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol 2014, 15:297-304.
10. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420.